TB-500 research, traced to the molecule each finding was measured on

What does TB-500 do at the cellular level?

TB-500 research begins with actin. The fragment carries the LKKTETQ motif that, in full-length thymosin β4, binds and sequesters monomeric (globular) actin. A 2 Å crystallographic study of a gelsolin-domain-1–Tβ4 hybrid bound to actin established that thymosin β4 forms a 1:1 complex with G-actin and caps both ends of the monomer, holding it out of polymerization ^[1]. By buffering the free-actin pool, the protein regulates cytoskeletal dynamics, cell migration, and motility — the upstream lever for most of its downstream repair effects ^[5].

The research-relevant point is the consequence: cells that migrate faster close wounds faster, build vessels faster, and repopulate damaged tissue faster. That is the engine behind the wound, cardiac, and stroke findings below — and, on the other side of the same trace, the reason the pro-migratory mechanism is itself a TB-500 side effects and safety signals concern.

How does TB-500 work?

TB-500 works, mechanistically, by carrying thymosin β4's actin-binding motif. The parent protein sequesters monomeric G-actin 1:1, regulating cytoskeletal assembly and cell migration ^[1], and is associated with angiogenesis and with anti-inflammatory and anti-scarring signaling in injury models ^[5]. In cardiomyocytes, full-length Tβ4 forms a complex with PINCH and integrin-linked kinase that activates the survival kinase Akt ^[2]. Whether the isolated seven-residue fragment reproduces this signaling cascade in humans is not established.

Thymosin Beta-4: the parent protein behind TB-500

Thymosin beta-4 is the molecule almost every TB-500 efficacy claim actually rests on. It is a ubiquitous 43-amino-acid peptide (~4963 Da), the body's principal G-actin-sequestering molecule, released by platelets and macrophages after injury to limit apoptosis, inflammation, and microbial growth while promoting cell mobilization and angiogenesis ^[5][10]. A multi-functional review framed it as an actin-sequestering protein that "moonlights" to repair injured tissue, integrating the cytoskeletal and regenerative roles into one account ^[10].

This is the central caveat of the entire TB-500 record. The fragment sold and detected as TB-500 is the 889 Da Ac-LKKTETQ heptapeptide; the protein studied for wound, cardiac, neurological, and hair-follicle repair is the 4963 Da full-length Tβ4. The two are described together by regulators because the fragment is derived from the protein, but they are not interchangeable as evidence. The same parent protein is also the one implicated in cancer overexpression ^[8] — so the identity distinction cuts both ways: it qualifies the benefit claims and it sharpens the risk ones.

Reported effects and TB-500 benefits in research models

The reported benefits of TB-500 in the literature cluster into tissue repair, cardiovascular and neurological recovery, angiogenesis, and hair-follicle activation — each a thymosin β4 finding in an animal or in-vitro model, not a demonstrated human outcome. In a rat full-thickness wound, thymosin β4 raised re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, increased wound contraction by at least 11% by day 7, and raised collagen deposition and angiogenesis ^[3]. A combined-endpoint study reported concurrent angiogenesis, wound-healing, and hair-follicle effects in rodents ^[14]. These are real, replicated effects of the full-length protein.

What the literature does not contain is a controlled human trial showing the TB-500 fragment delivers any of these outcomes in people. The benefit list is a list of mechanisms and animal results, surfaced plainly as such. The honest counterweight — the null mdx strength result ^[9] and the tumor-angiogenesis signal ^[7][8] — belongs on the same readout, which is why the TB-500 tumor-angiogenesis question is routed as a first-class page rather than an aside.

Does TB-500 work for muscle recovery? Thymosin β4 acts as a myoblast chemoattractant and has aided ligament healing in rats, but in dystrophin-deficient mice, six months of chronic Tβ4 increased regenerating fibers without improving muscle strength — a notable null functional result ^[9]. The community framing of TB-500 as a recovery agent rests on mechanism and animal data, not on a human muscle-recovery trial.

Cardiac, neurological, and connective-tissue findings

Does TB-500 affect the heart? In mice, thymosin β4 formed a functional complex with PINCH and integrin-linked kinase, activating Akt; after coronary artery ligation it upregulated ILK/Akt, enhanced early myocyte survival, and improved cardiac function ^[2]. These effects are shown for full-length Tβ4 in a rodent model and are not confirmed for the seven-residue fragment in humans.

Does TB-500 have neuroprotective effects? In male Wistar rats with embolic middle cerebral artery occlusion, intraperitoneal thymosin β4 at 2 and 12 mg/kg (starting 24 hours post-stroke, then every three days for four more doses) significantly improved neurological function from day 14 through day 56, while 18 mg/kg gave no significant benefit; a modeled optimal dose of about 3.75 mg/kg was proposed ^[4]. The non-monotonic shape is the headline here.

Can TB-500 help tendon and ligament repair? Thymosin β4 enhanced healing of medial collateral ligament injury in rats — one of the few direct connective-tissue findings — but this is preclinical and uses the full-length protein ^[5]. A structural-actin account ^[1] explains why a pro-migratory factor would aid connective-tissue repair, but the rat ligament result is the evidentiary anchor, not a human study.

Wound healing, hair, and inflammation

Does TB-500 help wound healing? Thymosin β4 accelerated re-epithelialization, contraction, collagen deposition, and angiogenesis in animal dermal and corneal wound models, and a dermal-healing review consolidated that record ^[3][11]. As little as 10 pg was active in keratinocyte migration assays ^[3] — picogram-scale potency that underscores how far the protein's effects sit from any "loading" rationale.

Does TB-500 increase hair growth? Nanomolar thymosin β4 activated hair-follicle bulge stem cells and accelerated hair growth in rodents ^[12][13][14]. This is animal data for the full-length protein, not a validated human hair-loss treatment.

Does TB-500 reduce inflammation? In vitro, thymosin β4 suppressed TNF-α–induced NF-κB activation and IL-8 — mechanistic evidence of an anti-inflammatory action rather than a clinical anti-inflammatory indication ^[5].

Are there human clinical trials on TB-500?

There are no completed controlled trials of the TB-500 heptapeptide for any indication. Human data exist only for full-length thymosin β4: a randomized, placebo-controlled Phase 1 intravenous safety and pharmacokinetic study in 40 healthy volunteers, well tolerated to 1260 mg with dose-proportional PK ^[6], plus topical ophthalmic Tβ4 (RGN-259) dry-eye trials. An injectable acute-myocardial-infarction study completed and an early injectable trial was withdrawn. Efficacy of the seven-residue fragment in humans is unproven.

What is the difference between TB-500 and BPC-157?

Both TB-500 and BPC-157 appear among the unapproved peptides studied for musculoskeletal repair in the 2026 Sports Med review, which concludes that such compounds show favorable animal repair signals but scarce human safety data and the potential for serious harm ^[15]. The molecules are distinct: TB-500 is the actin-binding thymosin β4 fragment, with a preclinical literature that is largely conducted on the full-length parent protein; BPC-157 is a separate pentadecapeptide with its own record. Neither is FDA-approved, and no controlled trial of the two used together exists. This site documents the TB-500 record only; a comparison is offered strictly as the literature frames it, with no claim of synergy.